Sugi Predict

Sugi Predict / Compounds / SCHEMBL2731512

SCHEMBL2731512

SCHEMBL2731512

O=C(O)c1ccccc1C1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ PTGDR2 Q9Y5Y4 1/20 0.50
▸ CYP2C9 P11712 1/20 0.49
▸ CAMKK2 Q96RR4 9/20 0.48
▸ CAMKK1 Q8N5S9 7/20 0.48
▸ ACMSD Q8TDX5 2/20 0.47
▸ CYP2D6 P10635 1/20 0.44
▸ SLC6A2 P23975 1/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ HMGB1 P09429 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL11642792 0.98 PTGDR2 (0.49) ALDH1A1ALOX15PTGDR2CYP2C9CAMKK2
SCHEMBL30730923 0.98 PTGDR2 (0.53) ALDH1A1ALOX15PTGDR2CYP2C9CAMKK2
SCHEMBL50486 0.98 PTGDR2 (0.53) ALDH1A1ALOX15PTGDR2CYP2C9CAMKK2
Ammonia Solution, Strong SCHEMBL29036685 0.96 PTGDR2 (0.51) ALDH1A1ALOX15PTGDR2CYP2C9CAMKK2
SCHEMBL3634253 0.96 ALDH1A1 (0.50) ALDH1A1ALOX15PTGDR2CYP2C9CAMKK2
SCHEMBL15648151 0.94 ALDH1A1 (0.48) ALDH1A1ALOX15PTGDR2CYP2C9CAMKK2
SCHEMBL4109572 0.92 ALDH1A1 (0.54) ALDH1A1ALOX15CYP2C9CYP2D6KDM4E
SCHEMBL10457353 0.92 ALDH1A1 (0.54) ALDH1A1ALOX15CYP2C9CYP2D6KDM4E
SCHEMBL30175300 0.92 ALDH1A1 (0.54) ALDH1A1ALOX15CYP2C9CYP2D6KDM4E
Hydrochloric Acid SCHEMBL29705669 0.90 ALDH1A1 (0.52) ALDH1A1ALOX15PTGDR2CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104916342-A Method for concentrating uranium from water solution with uranyl ions SHANGHAI INST APPLIED PHYSICS 2015-09-16 — — CN claimed
EP-4540238-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 — — EP disclosed
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-04-10 — — US disclosed
CN-116262692-B Preparation method of cyclopentanone 中国科学院大连化学物理研究所 2024-11-15 — — CN disclosed
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-07-25 — — US disclosed
CN-117597345-A Heterocyclic derivatives as CaMKK2 inhibitors 百时美施贵宝公司 2024-02-23 — — CN disclosed
WO-2023244818-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
CN-116262692-A Preparation method of cyclopentanone 中国科学院大连化学物理研究所 2023-06-16 — — CN disclosed
CN-106929036-A A kind of liquid-crystal compounds and its application containing cyclopenta and trifluoromethyl structure 北京八亿时空液晶科技股份有限公司 2017-07-07 — — CN disclosed
US-20170065575-A1 NAMPT INHIBITORS ABBVIE INC (US) 2017-03-09 — — US disclosed
US-7393958-B2 Triamide-substituted heterobicyclic compounds PFIZER, INC. (US) 2008-07-01 — — US disclosed
US-7368573-B2 Triamide-substituted heterobicyclic compounds PFIZER INC. (US) 2008-05-06 — — US disclosed
EP-1828121-A2 N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS Pfizer Limited (GB) 2007-09-05 — — EP disclosed
US-20070093525-A1 Triamide-substituted heterobicyclic compounds PFIZER INC 2007-04-26 — — US disclosed
CN-1914195-A Substituted quinoline compounds PFIZER PROD INC (US) 2007-02-14 — — CN disclosed
EP-1716137-A1 SUBSTITUTED QUINOLINE COMPOUNDS Pfizer Products Incorporated (US) 2006-11-02 — — EP disclosed
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS BERTINATO PETER 2006-10-05 — — US disclosed
WO-2006064336-A2 N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS PFIZER LIMITED (GB) 2006-06-22 — — WO disclosed
US-20050234099-A1 Substituted quinoline compounds PFIZER INC 2005-10-20 — — US disclosed
WO-2005080373-A1 SUBSTITUTED QUINOLINE COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS CAMKK2, CAMKK1, CAMK1 ALDH1A1 3614/4885ALOX15 2544/4885PTGDR2 551/4885
US-20170065575-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT ALDH1A1 1573/4885ALOX15 1919/4885PTGDR2 2803/4885
US-20050234099-A1 Substituted quinoline compounds APOB, APOL1, MTPN ALDH1A1 2807/4885ALOX15 2494/4885PTGDR2 4035/4885
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS APOB, MTPN, CTRB1 ALDH1A1 3299/4885ALOX15 2186/4885PTGDR2 3441/4885
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 ALDH1A1 1388/4885ALOX15 3734/4885PTGDR2 3264/4885
US-20070093525-A1 Triamide-substituted heterobicyclic compounds APOB, MTPN, CTRB1 ALDH1A1 3299/4885ALOX15 2186/4885PTGDR2 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.